一项随机，多中心，对照研究: 阿德 v 阿德+双环

StephenW

<http://www.mdlinx.com/gastroenterology/newsl-article.cfm/3693152/ZZ680655367925639220014/?news_id=511&newsdt=080211&subspec_id=144>

A randomized, multi-central, controlled study of patients with hepatitis B
e antigen-positive chronic hepatitis B treated by adefovir dipivoxil or
adefovir dipivoxil plus bicyclol

Hepatology International, 08/02/2011  Clinical Article

Xie W et al. – Adefovir dipivoxil plus bicyclol combination therapy is a
safe and superior treatment regimen for patients with HbeAg-positive
chronic hepatitis B(CHB) when compared with adefovir dipivoxil(ADV)
monotherapy.

Methods• Total of 250 patients with HBeAg-positive CHB were randomized to
ADV plus bicyclol combination group and ADV monotherapy group.

• Patients in the ADV plus bicyclol combination therapy group (n=125)
received ADV 10 mg orally q.d. and bicyclol 25 mg orally t.i.d. for 48
weeks, and those in the ADV monotherapy group (n=125) were administered ADV
10 mg orally q.d. alone for 48 weeks.

• Serum aminotransferases (ALT/AST), HBV DNA, HBeAg/HBeAb, and liver
biopsy were conducted before and after therapy.

Results• Serum aminotransferase levels were decreased significantly in
both groups.

• Serum aminotransferase level in ADV plus bicyclol combination therapy
group decreased greater than that in ADV monotherapy group (P< 0.01).

• Virological response rate in ADV plus bicyclol combination therapy
group was not significantly different from that in ADV monotherapy group
(P> 0.05).

• After treatment for 48 weeks, the Knodell necroinflammatory score of
the two groups were all alleviated significantly, and the Knodell score in
the combination group was significantly lower than that in the ADV
monotherapy group (P< 0.05).

• There were no remarkable adverse events probably related to the drug in
this study.

StephenW

谷歌翻译
不是100％准确，仅供参考使用。

一项随机，多中心，控制乙肝患者的研究
e抗原阳性的慢性乙肝阿德福韦治疗或
阿德福韦酯加双环

国际肝病，08/02/2011临床条

谢W等。 - 阿德福韦酯加双环醇联合治疗是一个
安全和优越的HBeAg阳性患者的治疗方案
与阿德福韦酯（ADV）相比，慢性乙型肝炎（CHB）
单药治疗。

方法•共有250例HBeAg阳性慢性乙型肝炎患者被随机分配到
ADV加双环醇联合治疗组和ADV单药治疗组。

•在ADV加双环醇联合治疗组的患者（N= 125）
收到ADV10 mg口服q.d.和双环醇25毫克口服每日三次48
周，并在ADV单药治疗组（N= 125）ADV管理
10毫克口服q.d.单独为48周。

•血清转氨酶（ALT / AST），乙肝病毒DNA，e抗原/ HBeAb和肝脏
治疗前后进行活检。

结果•血清转氨酶水平显着下降
这两个群体。

•ADV加双环醇结合治疗血清转氨酶水平
组下降大于ADV单药治疗组（P <0.01）。

•在ADV加双环联合治疗的病毒学应答率
组没有显着不同ADV单药治疗组
（P> 0.05）。

•后治疗48周，Knodell坏死性炎症评分
两组均明显缓解，而且Knodell评分
联合组显着低于该ADV
单药治疗组（P <0.05）。

•有可能与药物无明显不良反应事件
这项研究。